Actelion looks beyond promising results
Swiss company Actelion posted nine-month results for 2005 showing total net revenues of CHF477.1m (€310.1m), operating profit of CHF126.1m (€82m) and a resultant net profit of CHF103.8m (€67.5m). The company has consequently revised its full-year net revenue guidance from CHF600-615m (€390-400m) to CHF640-655m (€416-426m).
Tracleer sales reached CHF455.1m (€295.8m) for 2005, marking a significant increase on both an annual and a quarter-to-quarter basis, rising by 21% from CHF142.5m (€92.6m) to CHF172.9m (€112.4m). The pulmonary arterial hypertension drug is now approved in 34 countries and regulatory reviews are ongoing in others, including nine EU member states and some in South-East Asia. 'Financial results were outstanding as Tracleer sales continued to grow across all markets,' said Andrew J. Oakley, chief financial officer. 'In mid-June 2005 commercial sales began in Japan, and we expect this market to provide significant growth in 2006.'
The seven-year old company spent CHF121.2m (€78.8m) on r&d, in comparison to CHF98.1m (€63.8m) for the same period last year. 'Actelion has now made advances in implementing its long-term strategy of growing above and beyond Tracleer,' said Jean-Paul Clozel, md and ceo. 'It expects important clinical results from several pipeline projects within the next 18 months.'